VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate. These funds will be critical as the company transitions from preclinical to clinical stages, a capital-intensive phase for biotechnology firms.
The business combination and public listing provide VERAXA with access to capital markets and increased visibility among investors and potential partners. The BiTAC platform, founded on scientific breakthroughs made at the European Molecular Biology Laboratory, represents a novel approach to cancer therapy that aims to improve the therapeutic index of immunotherapies. By selectively engaging T cells to attack tumor cells while minimizing off-target effects, VERAXA hopes to address limitations of existing bispecific antibodies.
Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, was formed with the mission to revolutionize the healthcare sector through strategic combinations. The combined entity is now positioned to accelerate preclinical programs and prepare for investigational new drug (IND) filings. The successful completion of this transaction underscores the continued appetite for SPAC mergers in the biotech sector, particularly for platforms with differentiated technology and early clinical validation.
For regular updates about VERAXA Biotech, visit www.veraxa.com. More information about Voyager Acquisition Corp. can be found at https://www.voyageracq.com. The full press release is available at https://ibn.fm/ka00j.
